Patents Issued in January 28, 2014
  • Patent number: 8637038
    Abstract: Disclosed herein are methods for treating or inhibiting allograft rejection in a transplant recipient. In some embodiments, the methods include administering to the transplant recipient a first amount of a JAK1/3 inhibitor comprising 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3H)-one (Compound I) or a prodrug thereof and administering to the transplant recipient a second amount of a non-JAK1/3 inhibitor immunosuppressant, wherein the combined effect of the first amount and the second amount is greater than the effect of the first amount or the second amount individually, wherein the JAK1/3 inhibitor acts in combination with the non-JAK1/3 inhibitor immunosuppressant to inhibit or treat allograft rejection. In some embodiments at least one of the first amount or the second amount is individually a suboptimal dose for inhibiting or treating allograft rejection.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: January 28, 2014
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Vanessa Taylor, Esteban Masuda
  • Patent number: 8637039
    Abstract: The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: January 28, 2014
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Genticel
    Inventors: Xavier-Edmond-Edouard Preville, Claude Leclerc, Daniel Ladant, Benedikt Timmerman
  • Patent number: 8637040
    Abstract: Peptides generated from a random library that are bound by a monoclonal antibody to Chlamydial glycolipid exoantigen (GLXA) and thus mimic this antigen are disclosed. Peptides that correspond to antigen-binding regions of an anti-idiotypic antibody (mAb2) specific for anti-GLXA antibody (Ab1) which act as molecular mimics of GLXA are also disclosed used as immunogens to induce broadly reactive genus-specific anti-chlamydial antibodies. These peptides and immunogenic DNA encoding the mAb2-like peptides, microparticle or nanoparticle formulations and other formulations of these peptides are disclosed as are methods for immunizing subjects to obtain genus-specific anti-chlamydial antibodies and to treat or prevent Chlamydia-associated or induced rheumatoid arthritis.
    Type: Grant
    Filed: September 21, 2009
    Date of Patent: January 28, 2014
    Assignee: National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS)
    Inventors: Judith Whittum-Hudson, Alan P. Hudson
  • Patent number: 8637041
    Abstract: The invention relates to an immunogenic composition composed of secreted polypeptides derived from Campylobacter jejuni non-flagellar proteins that are coordinately expressed with the flagellar regulon. The invention also relates to a method of inducing an immune response to the non-flagellar protein polypeptides.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: January 28, 2014
    Assignee: The United States of America as Represented by the Secretary of the Navy
    Inventors: Patricia Guerry-Kopecko, Shahida Baqar
  • Patent number: 8637042
    Abstract: Drug delivery compositions and methods of delivering compounds are disclosed. Vaccines and methods of immunizing individuals are disclosed. Compositions for drug delivery including gene therapy and methods of treating individuals using such compositions are disclosed.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: January 28, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: David B Weiner, Karuppiah Muthumani, Donghui Zhang, Mathura Ramanathan
  • Patent number: 8637043
    Abstract: The inventors have discovered that a CK?8-1 truncation variant, CK?8-1 (25-116), is a bifunctional ligand for two distinct GPCRs, chemokine receptor CCR1 and formyl peptide receptor like 1 (FPRL1). Hence, the inventors have discovered that, in addition to its functional activity on CCR1, CK?8-1(25-116) is also a functional ligand for the GPCR receptor FPRL1 that is involved in inflammatory reactions and innate immunity by recruiting monocytes and neutrophils. In addition, the inventors have discovered an alternatively spliced exon of CK?8-1, named SHAAGtide. SHAAGtide, along with its parent chemokine CK?8-1 (25-116), is fully functional on both monocytes and neutrophils that are known to express FPRL1. This application relates generally to enhancing immune responses. Such immune responses may be elicited by vaccine administration. Compositions and methods for inducing or enhancing an immune response to an antigen are provided.
    Type: Grant
    Filed: July 5, 2005
    Date of Patent: January 28, 2014
    Assignee: Chemocentryx, Inc.
    Inventors: Thomas J. Schall, Zhenhua Miao, Robert Berahovich, Zheng Wei, Maureen Howard, Brett Premack
  • Patent number: 8637044
    Abstract: Hybrid molecules comprising CD4 minimal modules or mimetics that bind to HIV Env polypeptides in combination with one or more HIV Tat polypeptides are described. Also described are complexes of these hybrid molecules with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis AG
    Inventors: Susan Barnett, Rino Rappuoli, Victoria A Sharma, Indresh K Srivastava, Jan Zur Megede
  • Patent number: 8637045
    Abstract: The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 28, 2014
    Assignee: University of Massachusetts
    Inventors: Edward I. Ginns, Gary R. Ostroff
  • Patent number: 8637046
    Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: January 28, 2014
    Assignees: Cornell University, Novartis AG
    Inventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
  • Patent number: 8637047
    Abstract: The present invention provides a composition and an improved single dose vaccine against E. rhusiopathiae and an improved single dose vaccine against E. rhusiopathiae and H. parasuis which provides one or more of the following: 1) confers effective immunity against E. rhusiopathiae and/or H. parasuis; 2) decreases the risk of developing clinical signs of E. rhusiopathiae and/or H. parasuis infection; 3) induces an immune response against E. rhusiopathiae and/or H. parasuis; and 4) has a DOI against E. rhusiopathiae and/or H. parasuis of at least four months. The composition or E. rhusiopathiae vaccine as well as the combined E. rhusiopathiae-H. parasuis composition or vaccine each includes a bacterial component of inactivated E. rhusiopathiae bacteria and a suitable adjuvant. The combined E. rhusiopathiae-H. parasuis composition or vaccine further includes an amount of H. parasuis antigen. The vaccines can be administered to animals in any conventional manner.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: January 28, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: John Randall Swart, Eric Martin Vaughn, Karen E. Freking, Michael B. Roof, Phillip Wayne Hayes, Reid C. Phillips
  • Patent number: 8637048
    Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.
    Type: Grant
    Filed: April 21, 2011
    Date of Patent: January 28, 2014
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 8637049
    Abstract: Safe and effective live vaccines against bacteria infecting aquatic animals were created through the induction of novobiocin-resistance in liquid culture and novobiocin- and rifampicin-resistance in liquid culture.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: January 28, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Yuping Wei Pridgeon, Phillip H. Klesius
  • Patent number: 8637050
    Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: January 28, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Bernard W. Beall, George M. Carlone, Jacquelyn S. Sampson, Edwin W. Ades
  • Patent number: 8637051
    Abstract: The present invention is concerned with novel compositions and vaccines useful for prophylactic an/or therapeutic treatment of mucosal infections, and in particular it is concerned with oral vaccines and with methods of enhancing mucosal resistance to infection or for treating established infections, of the respiratory tract.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: January 28, 2014
    Assignee: Hunter Immunology Limited
    Inventors: Robert Llewellyn Clancy, Gerald Pang, Margaret Lorraine Dunkley
  • Patent number: 8637052
    Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: January 28, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander Von Gabain
  • Patent number: 8637053
    Abstract: Chlamydia antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as Chlamydia, in a subject.
    Type: Grant
    Filed: December 3, 2008
    Date of Patent: January 28, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: Darren E. Higgins, Todd Gierahn
  • Patent number: 8637054
    Abstract: This invention concerns an ophthalmic solution including: at least one prostaglandin; a solubilizing agent; a gelling agent of the carbomer type; a carbomer polymerization-inhibiting agent; a co-gelling/co-solubilizing agent.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: January 28, 2014
    Assignee: Laboratoires Thea
    Inventor: Fabrice Mercier
  • Patent number: 8637055
    Abstract: The present invention present a novel and cost-effective family of cosmetic compositions comprising inter alia small magnetic particles characterized by magnetic field adapted to be topically administrated adjacent to skin surface, absorbed to epidermal upper skin layers and place in a direct contact to the body, usually above pain suffering regions. The present invention also provides the use of the compositions, especially of nano-powders of salts obtained from the Dead Sea, as an external layer of bandages, dressings, compresses or warps, so constantly approached to be in an intimate contact with the patient's skin.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: January 28, 2014
    Assignee: Ahava-Dead Sea Laboratories Ltd.
    Inventors: Zeev Maor, Michael Royz
  • Patent number: 8637056
    Abstract: Mixture comprising esters of saturated C16-C18 fatty acid and unsaturated C16-C18 fatty acids with 2-ethyl-hexyl alcohol, said esters being in an amount ranging from 90% to 100% by weight with respect to the total weight of the mixture. The cosmetic compositions containing such a mixture formulated in topical form have a moisturizing, emollient, elasticizing and skin compactness and smoothness improving action.
    Type: Grant
    Filed: October 15, 2009
    Date of Patent: January 28, 2014
    Assignee: Hallstar Italia S.R.L.
    Inventors: Sergio Amari, Edoardo Pallucca
  • Patent number: 8637057
    Abstract: Disclosed are cosmetic compositions in the form of an emulsion that contain an uncoated silicone elastomer, a solvent for the elastomer, a non-silicone treated pigment and an emulsifier, methods of making the compositions, and methods of applying the compositions to a keratinous substrate or tissue.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: January 28, 2014
    Assignee: L'Oreal
    Inventors: Dhaval Patel, Gisela Perruna
  • Patent number: 8637058
    Abstract: Composition for controlling phytopathogens comprising compound of the formula: wherein: R1 represents H, or a CO—R? acyl group; R2, the same or different when n is equal to 2, is a halogen, optionally selected from fluorine, chlorine, bromine or iodine; a C1-C9 alkyl group; a C1-C9 haloalkyl group; a C1-C9 alkoxyl group; a C1-C9 haloalkoxyl group; a C1-C9 thioalkyl group; a C1-C9 halothioalkyl group; a C3-C9 cycloalkyl group; a C2-C10 carboalkoxyl group; a cyano group; a hydroxyl group; R? represents a hydrogen; a C1-C9 alkyl group; a C1-C9 haloalkyl group; a C1-C9 alkoxyl group; a C1-C9 haloalkoxyl group; a C2-C10 carboalkoxyl group; a phenyl group; n is a number ranging from 0 to 2; X represents an oxygen atom, a nitrogen or sulfur atom in combination with a fungicide; method for controlling phytopathogens with compound of formula (1) with or without another fungicide.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: January 28, 2014
    Assignee: Isagro S.p.A.
    Inventors: Lucio Filippini, Marilena Gusmeroli, Alexia Elmini, Carlo Garavaglia, Luigi Mirenna
  • Patent number: 8637059
    Abstract: The present invention relates to mixtures comprising as active components a) carbamate derivatives of the formula (I) in which the substituents and the index have the following meaning: T is CH or N n is 0, 1 or 2 R is halogen, C1-C4-alkyl or C1-C4-haloalkyl, it being possible for the radicals R to be different when n is 2, and b) at least one compound of the formula (II).
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: January 28, 2014
    Assignee: BASF SE
    Inventors: Edson Begliomini, Sergio Zambon
  • Patent number: 8637060
    Abstract: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation which is convenient for local application to the animal's skin, preferably localized over a small surface area.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: January 28, 2014
    Assignee: Sergeant's Pet Care Products, Inc.
    Inventor: Larry Nouvel
  • Patent number: 8637061
    Abstract: A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: January 28, 2014
    Assignee: Magceutics, Inc.
    Inventors: Guosong Liu, Fei Mao
  • Patent number: 8637062
    Abstract: Implant provided with a coating, with the implant being provided with an amino-functionalized parylene coating, an oligonucleotide and/or an oligopeptide having a specific bonding affinity with CD34-positive cells.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: January 28, 2014
    Inventors: Lothar Sellin, Bock-Sun Han, Annelotte Autschbach
  • Patent number: 8637063
    Abstract: The invention provides methods of making hydrolyzed cross-linked polyvinyl alcohol (PVA) hydrogels by polymerizing vinyl acetate (VAc) monomers to polyvinyl acetate (PVAc) polymer network by chemical-crosslinking and hydrolysis. The invention also provides methods for including pendant chains in the hydrogel during the polymerization process. Materials produced and use of the cross-linked hydrolyzed PVA hydrogels also are disclosed herein.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: January 28, 2014
    Assignee: Cambridge Polymer Group, Inc.
    Inventors: Edward T. Kopesky, Jason Berlin, Martin F. Van Buren, Gavin J. C. Braithwaite
  • Patent number: 8637064
    Abstract: A process for making an implantable material comprising a composite of a biocompatible polymer and a bioactive agent. The composite combines desirable mechanical properties of polymers and the bioactivity of tissue or one or more component of tissue. More particularly, but not exclusively, the invention relates to methods for the manufacture of implantable materials, devices and components via a powder molding process.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: January 28, 2014
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: SuPing Lyu, Christopher M. Hobot, Sean M. Haddock, Brian A. Loy, Randall V. Sparer, K. Matthew Kinnane, Jeffrey M. Gross
  • Patent number: 8637065
    Abstract: Methods for inducing differentiation of dermis-derived cells to serve as a source of chondrocytes and associated methods of use in forming tissue engineered constructs. One example of a method is a method for inducing differentiation of cells into chondrocytes comprising providing aggrecan sensitive isolated dermis cells and seeding the cells onto an aggrecan coated surface.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: January 28, 2014
    Assignee: William Marsh Rice University
    Inventors: Kyriacos A. Athanasiou, Ying Deng, Jerry Hu
  • Patent number: 8637066
    Abstract: A biocompatible ligament repair implant or scaffold device is provided for use in repairing a variety of ligament tissue injuries. The repair procedures may be conducted with ligament repair implants that contain a biological component that assists in healing or tissue repair. The biocompatible ligament repair implants include a biocompatible scaffold and particles of viable tissue derived from ligament tissue or tendon tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: January 28, 2014
    Assignee: DePuy Mitek, LLC
    Inventors: Francois Binnette, Julia Hwang, Mark Zimmerman, Mora Carolynne Melican
  • Patent number: 8637067
    Abstract: A tissue-derived hydrogel, as well as methods of making and using such hydrogels, are provided.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: January 28, 2014
    Assignee: LifeCell Corporation
    Inventors: Wenquan Sun, Hui Xu, Hua Wan
  • Patent number: 8637068
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: January 28, 2014
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 8637069
    Abstract: A method including introducing a treatment agent at a treatment site within a mammalian host; and introducing a bioerodable gel material at the treatment site. An apparatus including a first annular member having a first lumen disposed about a length of the first annular member and a first entry port at a proximal end of the first annular member, and a second annular member coupled to the first annular member having a second lumen disposed about a length of the second annular member and a second entry port at a proximal end of the second annular member, wherein the first annular member and the second annular member are positioned to allow a combining of treatment agents introduced through each annular member at the treatment site.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: January 28, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: Charles D. Claude, Paul J. Kawula, Syed Faiyaz Ahmed Hossainy, Kimchi Tran
  • Patent number: 8637070
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: January 28, 2014
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Patent number: 8637071
    Abstract: The present invention provides a method for preparing a medical device, preferably a contact lens, having an antimicrobial metal-containing LbL coating on a medical device, wherein the antimicrobial metal-containing LbL coating comprises at least one layer of a negatively charged polyionic material having —COOAg groups and/or silver nanoparticles formed by reducing Ag+ ions associated with the —COO? groups of the negatively charged polyionic material. In addition, the present invention provides a medical device prepared according to a method of the invention.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis AG
    Inventors: Michael F. Rubner, Sung Yun Yang, Yongxing Qiu, Lynn Cook Winterton, John Martin Lally
  • Patent number: 8637072
    Abstract: The present invention relates to wound dressings, in particular to an antibacterial wound dressing based on silvered gel-forming fabric and to a process for the manufacture of such a wound dressing.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: January 28, 2014
    Assignee: Convatec Technologies, Inc.
    Inventors: David Kershaw, Barry DeBoorder, Stephen John Law
  • Patent number: 8637073
    Abstract: Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form can be administered for a first dosing period that is no more than about 5 days; a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.
    Type: Grant
    Filed: July 26, 2004
    Date of Patent: January 28, 2014
    Assignee: Purdue Pharma L.P.
    Inventors: Bruce E. Reidenberg, Daniel A. Spyker
  • Patent number: 8637074
    Abstract: This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: January 28, 2014
    Assignee: Aphios Corporation
    Inventor: Trevor Percival Castor
  • Patent number: 8637075
    Abstract: The present invention relates to a composition comprising colostrum and at least one agent selected from the group of hydrocolloids, wherein said colostrum and at least one agent are bioconjugated. The bioconjugated composition has improved properties compared to colstrum compositions that are not bioconjugated with a hydrocolloid agent. The composition may be used in a variety of settings, for example for topical application for treating skin diseases and skin conditions. The present invention thus also relates to use of the composition and to a method for the preparation of the composition.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: January 28, 2014
    Assignee: Pharma GP ApS
    Inventors: Ninfa Rangel Pedersen, Steen Palle
  • Patent number: 8637076
    Abstract: The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: January 28, 2014
    Assignee: Cima Labs Inc.
    Inventors: Walid Habib, Bhaveshkumar Kothari
  • Patent number: 8637077
    Abstract: Sustained release preparations, which show suppressed initial release of a physiologically active substance and can release a constant amount of the physiologically active substance over a long period of time, and dispersion vehicle thereof can be obtained by adding a cationic substance or polyols to the outside of a matrix or dispersion vehicle thereof. Thus, sustained release preparations, which show suppressed initial release of a physiologically active substance immediately after the administration and can release a constant amount of the physiologically active substance over a long period of time and dispersion vehicle thereof can be provided.
    Type: Grant
    Filed: December 26, 2001
    Date of Patent: January 28, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shigeyuki Takada, Masafumi Misaki, Kenji Nakamura
  • Patent number: 8637078
    Abstract: The invention relates to a bilayer pharmaceutical tablet comprising a first layer containing 3 to 50 wt. % of telmisartan dispersed in a dissolving tablet matrix and a second layer containing a diuretic in a disintegrating tablet matrix as well as a processes for producing same.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: January 28, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Manabu Nakatani, Kazutoshi Yokoyama, Takeshi Sawada
  • Patent number: 8637079
    Abstract: A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: January 28, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura
  • Patent number: 8637080
    Abstract: The present invention provides a simple and improved rupturing controlled release device that is capable of providing a controlled release of active agent contained in the core first through a preformed passageway and then through an in situ formed second passageway into an environment of use in a standardized release profile manner. The rupturing controlled release device comprises a core comprising at least one drug and at least one osmopolymer, a semipermeable membrane enclosing the core and having at least one preformed passageway there through, wherein the semipermeable membrane ruptures during use to form a second passageway in the semipermeable membrane at a location spaced away from the preformed passageway, and a release-controlling subcoat between the core and the semipermeable membrane.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: January 28, 2014
    Assignee: Osmotica Kereskedelmi és Szolgáltató, KFT
    Inventors: Ana C. Pastini, Joaquina Faour, Juan A. Vergez, Marcelo A. Ricci, Gustavo A. Fischbein
  • Patent number: 8637081
    Abstract: A therapeutic composition comprising gelatin and a cross-linking agent, for use in biological regenerative methods, which composition can be administered to a target area of the body while ensuring that the suspended cells and/or the growth factors remain in the target area of the body and at the same time eliminating the need for the patient to maintain the treated body area immobilized for unreasonable periods, is disclosed. A method is also disclosed, wherein (i) the gelatin and the cross-linking agent are mixed with each other to form the cross-linking therapeutic composition which is then administered to the target area; or (ii) the gelatin and the cross-linking agent are made available in separate form and are administered, simultaneously or one after the other, to the target area while forming the cross-linking therapeutic composition.
    Type: Grant
    Filed: January 8, 2009
    Date of Patent: January 28, 2014
    Assignee: TETEC Tissue Engineering Technologies AG
    Inventors: Christophe Gaissmaier, Michael Ahlers
  • Patent number: 8637082
    Abstract: Nanocrystals having a ZnTe core and methods for making and using them to construct core-shell nanocrystals are described. These core-shell nanocrystals are highly stable and provide quantum yields and stability suitable for applications such as flow cytometry, cellular imaging, and protein blotting, medical imaging, and other applications where cadmium toxicity is an issue.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: January 28, 2014
    Assignee: Life Technologies Corporation
    Inventors: Eric Tulsky, Joseph Bartel, Joseph Treadway
  • Patent number: 8637083
    Abstract: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: January 28, 2014
    Assignee: BIND Therapeutics, Inc.
    Inventors: Greg Troiano, Young-Ho Song, Stephen E. Zale, James Wright, Christina Van Geen Hoven
  • Patent number: 8637084
    Abstract: It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising: step (a) of selectively reducing KLRG1-positive immunocytes in the peripheral blood of a living individual with epithelial cancer ex vivo, which is positive for a cancer-specific membrane antigen expressed in epithelial cancer cells and positive for a KLRG1 ligand; and step (b) of administering, to the living individual, a therapeutic agent for cancer comprising an antibody reacting with the cancer-specific membrane antigen expressed in epithelial cancer cells and having antibody-dependent cell cytotoxicity.
    Type: Grant
    Filed: July 13, 2010
    Date of Patent: January 28, 2014
    Assignees: Asahi Kasei Medical Co., Ltd., National Cancer Center
    Inventors: Mikitomo Yasutake, Kasumi Ninomiya, Junichi Honda, Atsushi Ochiai, Chisako Yamauchi
  • Patent number: 8637085
    Abstract: An aqueous disinfecting solution having a pH from about 0.5 to about 6 and consisting essentially of hydrogen peroxide in a concentration from about 0.05 to about 8 w/w % of the total solution; at least one anionic surfactant in a concentration from about 0.02 to about 8 w/w % of the total solution, selected from sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof; naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; and alkyl or alkenyl esters or diesters of sulfosuccinic acids in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof; and benzyl alcohol in a concentration from about 0.1 to about 10 w/w % of the solution.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Virox Technologies Inc.
    Inventors: Jose A. Ramirez, Navid Omidbakhsh
  • Patent number: 8637086
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: January 28, 2014
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Patent number: 8637087
    Abstract: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-?8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-?8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-?8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: January 28, 2014
    Assignee: JB Therapeutics Inc.
    Inventors: Bobby W. Sandage, Jr., Glenn L. Cooper